Patents Examined by Rehana Ismail
  • Patent number: 12016862
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: June 25, 2024
    Assignee: GENENTECH, INC
    Inventors: Marie Evangelista, Mark Andrew Merchant, Jennifer Lee Schutzman, Ting-Kun Mark Lin, Stephanie Royer Joo, Sandhya Vinayak Mandlekar, Stuart G. Lutzker
  • Patent number: 12018009
    Abstract: Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and/or anxiety disorder, each individually or concurrent.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: June 25, 2024
    Assignee: AMYGDALA NEUROSCIENCES, INC.
    Inventor: Brent Blackburn
  • Patent number: 12012407
    Abstract: Novel pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-3-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-3-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: January 31, 2024
    Date of Patent: June 18, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 11987581
    Abstract: Novel imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: December 19, 2023
    Date of Patent: May 21, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun